These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
116 related items for PubMed ID: 2091663
1. Immunogenicity of liposome-associated oral cholera vaccine prepared from combined Vibrio cholerae antigens. Chaicumpa W, Parairo JR, New RC, Pongponratn E, Ruangkunaporn Y, Tapchaisri P, Chongsa-nguan M. Asian Pac J Allergy Immunol; 1990 Dec; 8(2):87-94. PubMed ID: 2091663 [Abstract] [Full Text] [Related]
2. CpG DNA, liposome and refined antigen oral cholera vaccine. Leelawongtawon R, Somroop S, Chaisri U, Tongtawe P, Chongsa-nguan M, Kalambaheti T, Tapchaisri P, Pichyangkul S, Sakolvaree Y, Kurazono H, Hayashi H, Chaicumpa W. Asian Pac J Allergy Immunol; 2003 Dec; 21(4):231-9. PubMed ID: 15198341 [Abstract] [Full Text] [Related]
3. Immunogenicity and protective role of three formulations of oral cholera vaccine. Kalambaheti T, Chaisri U, Srimanote P, Pongponratn E, Chaicumpa W. Vaccine; 1998 Dec; 16(2-3):201-7. PubMed ID: 9607031 [Abstract] [Full Text] [Related]
4. Immunogenicity of liposome-associated and refined antigen oral cholera vaccines in Thai volunteers. Chaicumpa W, Chongsa-nguan M, Kalambaheti T, Wilairatana P, Srimanote P, Makakunkijcharoen Y, Looareesuwan S, Sakolvaree Y. Vaccine; 1998 Apr; 16(7):678-84. PubMed ID: 9562686 [Abstract] [Full Text] [Related]
9. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. García L, Jidy MD, García H, Rodríguez BL, Fernández R, Año G, Cedré B, Valmaseda T, Suzarte E, Ramírez M, Pino Y, Campos J, Menéndez J, Valera R, González D, González I, Pérez O, Serrano T, Lastre M, Miralles F, Del Campo J, Maestre JL, Pérez JL, Talavera A, Pérez A, Marrero K, Ledón T, Fando R. Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509 [Abstract] [Full Text] [Related]
10. Immunogenicity of two formulations of oral cholera vaccines in Thai volunteers. Chongsa-nguan M, Chaicumpa W, Ruangkunaporn Y, Looareesuwan S. Vaccine; 1991 Jan; 9(1):53-9. PubMed ID: 2008802 [Abstract] [Full Text] [Related]
11. Formulation in tablets of a cholera whole cells inactivated vaccine candidate. Talavera A, Año G, Pino Y, Castaño J, Uribarri E, Riverón L, Gil S, Fernández S, Cedré B, Valmaseda T, Pérez JL, Infante JF, García L, Sierra G. Vaccine; 2006 Apr 12; 24(16):3381-7. PubMed ID: 16460846 [Abstract] [Full Text] [Related]
12. Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles. Yeh MK, Liu YT, Chen JL, Chiang CH. J Control Release; 2002 Aug 21; 82(2-3):237-47. PubMed ID: 12175740 [Abstract] [Full Text] [Related]
17. A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae. Año G, Esquisabel A, Pastor M, Talavera A, Cedré B, Fernández S, Sifontes S, Aranguren Y, Falero G, García L, Solís RL, Pedraz JL. Vaccine; 2011 Aug 05; 29(34):5758-64. PubMed ID: 21683110 [Abstract] [Full Text] [Related]
19. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. Albert MJ, Alam K, Rahman AS, Huda S, Sack RB. J Infect Dis; 1994 Mar 05; 169(3):709-10. PubMed ID: 8158063 [No Abstract] [Full Text] [Related]